DMAC

Diamedica Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 0/10
  • Value↑ 5/10
Diamedica Therapeutics sales and earnings growth
DMAC Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -10.94%
  • FCF Y/Y↓ -37.31%
Diamedica Therapeutics gross and profit margin trends
DMAC Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -62.33%
Diamedica Therapeutics net debt vs free cash flow
DMAC Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Diamedica Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks